600613 Stock Overview
Operates as a pharmaceutical manufacturing holding investment company in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.19 |
| 52 Week High | CN¥9.31 |
| 52 Week Low | CN¥4.65 |
| Beta | 0.62 |
| 1 Month Change | -5.21% |
| 3 Month Change | -1.59% |
| 1 Year Change | -13.31% |
| 3 Year Change | 12.55% |
| 5 Year Change | -5.35% |
| Change since IPO | -21.42% |
Recent News & Updates
Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem
May 06
Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking
Apr 17Shareholder Returns
| 600613 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.5% | -2.0% | -1.5% |
| 1Y | -13.3% | -13.0% | -11.8% |
Return vs Industry: 600613 matched the CN Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: 600613 underperformed the CN Market which returned -11.8% over the past year.
Price Volatility
| 600613 volatility | |
|---|---|
| 600613 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 600613 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600613's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 1,426 | Feng Bin | www.gzsq.com |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, nourishing and soothing, tonic products, cold and cough, children's medicine, anti-fungal, gynecology, and other treatment fields. Its products include prescription drugs and OTC products, including products include sodium cantharidate vitamin B6 injection, sodium cantharidate injection, loquat cough granules, strong loquat decoction, loquat cough capsules, jinwugutong capsules, coral ringworm jing, jingwu capsules, quantianma capsules, yindanxintai dropping pills, etc. The company was founded in 1990 and is based in Shanghai, China.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Fundamentals Summary
| 600613 fundamental statistics | |
|---|---|
| Market cap | CN¥3.16b |
| Earnings (TTM) | CN¥57.15m |
| Revenue (TTM) | CN¥2.33b |
57.8x
P/E Ratio1.4x
P/S RatioIs 600613 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600613 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.33b |
| Cost of Revenue | CN¥1.20b |
| Gross Profit | CN¥1.14b |
| Other Expenses | CN¥1.08b |
| Earnings | CN¥57.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 48.77% |
| Net Profit Margin | 2.45% |
| Debt/Equity Ratio | 10.1% |
How did 600613 perform over the long term?
See historical performance and comparison